The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - AstraZeneca Japan (I); Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD K.K; Novartis; Ono Pharmaceutical
Research Funding - Bristol-Myers Squibb; Ono Pharmaceutical
Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.
 
Eiji Shinozaki
Honoraria - Chugai Pharma; Lilly; Merck Serono; Novartis; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Akihito Kawazoe
Research Funding - Dainippon Sumitomo Pharma (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Yasutoshi Kuboki
Honoraria - Bayer; Lilly Japan; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Daiichi Sankyo; Incyte (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Yoshito Komatsu
Honoraria - Bayer; Novartis; Pfizer
Speakers' Bureau - Bayer; Chugai Pharma; Lilly; Merck Serono; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Bayer; Chugai Pharma; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Pharmaceutical
 
Tomohiro Nishina
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Hiroki Hara
Honoraria - Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Chugai Pharma; Merck Serono; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Incyte (Inst); Lilly (Inst); LSK BioPharma (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Satoshi Yuki
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Lilly; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Hideaki Bando
Research Funding - AstraZeneca; Sysmex
 
Daisuke Kotani
No Relationships to Disclose
 
Koji Takahashi
Employment - EPS Corporation
 
Yuichi Mikamoto
Employment - Mitsubishi Tanabe Pharma
 
Hiromi Hasegawa
No Relationships to Disclose
 
Nami Hirano
No Relationships to Disclose
 
Shogo Nomura
Employment - Asahi Kasei
 
Yosuke Togashi
No Relationships to Disclose
 
Hiroyoshi Nishikawa
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Ono Pharmaceutical
Research Funding - Bristol-Myers Squibb; Daiichi Sankyo; Kyowa Hakko Kirin; Ono Pharmaceutical; Taiho Pharmaceutical; Zenyaku Kogyo
 
Akihiro Sato
Honoraria - AstraZeneca; Dainippon Sumitomo Pharma
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst)
 
Atsushi Ohtsu
Employment - Celgene (I)
Research Funding - Bristol-Myers Squibb
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Lilly Japan; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); GlaxoSmithKline K.K. (Inst)